[Clinical and hemodynamic effects of medium-term treatment with muzolimine in subjects with essential arterial hypertension].
The antihypertensive effects and haemodynamic changes after administration of 30 mg/die of muzolimine for 30 days in a group of patients with mild or moderate essential hypertension have been evaluated. Our findings showed a significant reduction of body weight, arterial blood pressure, systemic vascular resistance, plasma volume and small but significant increase of left ventricular ejection fraction. No relevant side effect have been observed.
D000328:Adult; D001835:Body Weight / Q000187:drug effects; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009156:Muzolimine / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D013997:Time Factors
D011720:Pyrazoles; D009156:Muzolimine
Effetti clinici ed emodinamici del trattamento a medio termine con muzolimina in soggetti con ipertensione arteriosa essenziale.